دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome
Tjerk S.J.OpstalMDabAernoud T.L.FioletMDcdAmbervan BroekhovenMDaArendMosterdMD, PhDdeJohn W.EikelboomMD, PhDfStefan M.NidorfMD, PhDghPeter L.ThompsonMD, PhDgijMichielDuyvendakPharmD, PhDklJ.W. Martijnvan EckMD, PhDmEugène A.van BeekMD, PhDnFrankden HartogMD, PhDoCharley A.BudgeonPhDjWillem A.BaxMD, PhDpJan G.P.TijssenPhDqrSalouaEl MessaoudiMD, PhDaJan H.CornelMD, PhDabd
doi : 10.1016/j.jacc.2021.06.037
Volume 78, Issue 9, 31 August 2021, Pages 859-866
Colchicine reduces risk of cardiovascular events in patients post–myocardial infarction and in patients with chronic coronary disease. It remains unclear whether this effect is related to the time of onset of treatment following an acute coronary syndrome (ACS).
Low-Dose Colchicine for the Management of Coronary Artery Disease?
Jean-ClaudeTardifMDGuillaumeMarquis-GravelMD, MSc
doi : 10.1016/j.jacc.2021.07.002
Volume 78, Issue 9, 31 August 2021, Pages 867-869
Pregnancy-Related Aortic Complications in Women With Marfan Syndrome
NupoorNarulaMDRichard B.DevereuxMDGrace P.MalongaMPHIngridHriljacMDMary J.RomanMD
doi : 10.1016/j.jacc.2021.06.034
Volume 78, Issue 9, 31 August 2021, Pages 870-879
The risk of pregnancy-associated vascular complications in Marfan syndrome (MFS) is uncertain because of ascertainment bias, prepartum lack of knowledge of diagnosis, and insufficient peripartum imaging data. Furthermore, U.S. and European guidelines differ in pregnancy recommendations in MFS.
Further Evidence for the Safety Considerations in Pregnancy of Women With Marfan Syndrome?
Melissa L.RussoMDaAnji T.YetmanMDb
doi : 10.1016/j.jacc.2021.07.010
Volume 78, Issue 9, 31 August 2021, Pages 880-882
Contemporary Left Ventricular Assist Device Outcomes in an Aging Population: An STS INTERMACS Analysis
DominicEmersonMDaJoannaChikweMDaPedroCatarinoMDaMohamedHassaneinMD, PhDaLuqinDengPhDbRyan S.CantorPhDbAmyRoachMDaRobertColeMDaFardadEsmailianMDaJonKobashigawaMDaJaimeMoriguchiMDaJames K.KirklinMDb
doi : 10.1016/j.jacc.2021.06.035
Volume 78, Issue 9, 31 August 2021, Pages 883-894
Survival, functional outcomes, and quality of life after left ventricular assist device (LVAD) are ill-defined in elderly patients, and with new-generation devices.
Is Durable Left Ventricular Assist Device Therapy a Viable Option for the Elderly??
Francis D.PaganiMD, PhD
doi : 10.1016/j.jacc.2021.07.001
Volume 78, Issue 9, 31 August 2021, Pages 895-897
Gender Differences in the Pursuit of Cardiac Electrophysiology Training in North America
NashwaAbdulsalamMBBChabAnne M.GillisMDcAnne K.RzeszutMAdCelina M.YongMD, MBA, MScefClaire S.DuvernoyMDgMarie-NoelleLanganMDhKristinWestBAiPoonamVelagapudiMDaSenaKillicMDjEdward L.O’LearyMD, MBA, MHCMa
doi : 10.1016/j.jacc.2021.06.033
Volume 78, Issue 9, 31 August 2021, Pages 898-909
Despite the increase in the number of female physicians across most specialties within cardiology, <10% of clinical cardiac electrophysiology (EP) fellows are women.
Getting Into the Rhythm of Gender Parity in Electrophysiology?
Erin D.MichosMD, MHSaAnnabelle SantosVolgmanMDbKamala P.TamirisaMDc
doi : 10.1016/j.jacc.2021.06.036
Volume 78, Issue 9, 31 August 2021, Pages 910-913
Cryoballoon Ablation as Initial Treatment for Atrial Fibrillation: JACC State-of-the-Art Review
Jason G.AndradeMDabcOussama M.WazniMDdMalteKunissMDeNathaniel M.HawkinsMDabMarc W.DeyellMD, MScabGian-BattistaChierchiaMDfStevenNissenMDdAtulVermaMDgGeorge A.WellsPhDhRicky D.TurgeonPharmDa
doi : 10.1016/j.jacc.2021.06.038
Volume 78, Issue 9, 31 August 2021, Pages 914-930
Atrial fibrillation (AF), the most common sustained arrhythmia observed in clinical practice, is a chronic and progressive disorder characterized by exacerbations and remissions. Guidelines recommend antiarrhythmic drugs as the initial therapy for the maintenance of sinus rhythm; however, antiarrhythmic drugs have modest efficacy to maintain sinus rhythm and can be associated with significant adverse effects. An initial treatment strategy of cryoballoon catheter ablation in patients with treatment-naïve AF has been shown to significantly improve arrhythmia outcomes (freedom from any, or symptomatic atrial tachyarrhythmia), produce clinically meaningful improvements in patient-reported outcomes (symptoms and quality of life), and significantly reduce subsequent health care resource use (hospitalization), and it does not increase the risk of serious or any adverse events compared with initial antiarrhythmic drug therapy. These findings are relevant to inform patients, providers, and health care systems regarding the initial choice of rhythm-control therapy in patients with treatment-naïve AF.
Device Therapy in Chronic Heart Failure: JACC State-of-the-Art Review
MaratFudimMD, MHSabWilliam T.AbrahamMDcRalph Stephanvon BardelebenMDdJoAnnLindenfeldMDePiotr P.PonikowskiMD, PhDfgHusam M.SalahMDhMuhammad ShahzebKhanMD, MSiHorstSievertMDjkGregg W.StoneMDlmStefan D.AnkerMDnopJavedButlerMD, MBA, MPHi
doi : 10.1016/j.jacc.2021.06.040
Volume 78, Issue 9, 31 August 2021, Pages 931-956
The regulatory landscape for device-based heart failure (HF) therapies has seen a major shift in the last 7 years. In 2013, the U.S. Food and Drug Administration released guidance for early feasibility and first-in-human studies, thereby encouraging device innovation, and in 2016 the U.S. Congress authorized the Breakthrough Devices Program to expedite access for Americans to innovative devices indicated for diagnosis and treatment of serious illnesses, such as HF. Since December 2016, there has been an increase in the number of HF devices for which manufacturers are seeking approval through the breakthrough designation pathway. This has led to a rapid uptake in the development and evaluation of device-based HF therapies. This article reviews the current and future landscape of device therapies for chronic HF and associated comorbidities and the regulatory environment that is driving current and future innovation.
The Ancient Heart: What the Heart Meant to Our Ancestors
Vincent MichaelFigueredoMD
doi : 10.1016/j.jacc.2021.06.041
Volume 78, Issue 9, 31 August 2021, Pages 957-959
2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee
Salim S.ViraniMD, PhD, FACC(Chair)Pamela B.MorrisMD, FACC(Vice Chair)AnanditaAgarwalaMDChristie M.BallantyneMD, FACCKim K.BirtcherPharmD, MS, CDE, AACCPenny M.Kris-EthertonPhD, RDAmanda B.Ladden-StirlingMPPMichaelMillerMD, FACCCarl E.OrringerMD, FACCNeil J.StoneMD, FACC
doi : 10.1016/j.jacc.2021.06.011
Volume 78, Issue 9, 31 August 2021, Pages 960-993
Innovation: Food, Nutrition, and the Promise of Heart Health
DiptiItchhaporiaMD, FACC(President, American College of Cardiology)
doi : 10.1016/j.jacc.2021.07.021
Volume 78, Issue 9, 31 August 2021, Pages 994-997
Oxalic Cardiomyopathy: Could it Influence Treatment Plans in Patients With Primary Hyperoxaluria Type 1?
AlessandroDi ToroMDMarioUrtisBMELorenzoGiulianiBSCarloPellegriniMD, PhDAlexandraSmirnovaPhDRaffaeleGalatoMDAdeleValentiniMDHusseinJallousMDSergioScaccabarozziMDEloisaArbustiniMD
doi : 10.1016/j.jacc.2021.06.039
Volume 78, Issue 9, 31 August 2021, Pages 998-999
